2023
Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.Peer-Reviewed Original Research
2020
Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas
Lee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.Peer-Reviewed Original ResearchT-cell lymphomaAggressive T-cell lymphomaWeekly dosing scheduleMycosis fungoides/Sezary syndromeMF/SSWeekly dosingCell lymphomaDosing schedulesBrentuximab vedotinSezary syndromeGamma-delta T-cell lymphomaWeekly scheduleNK-T cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaAnaplastic large cell lymphomaCancer response rateIncidence of neuropathyWeekly x 3Prospective clinical trialsStem cell transplantAdult T-cell leukemiaLarge cell lymphomaT-cell leukemiaDose weeklyA Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma
Mato A, Schuster S, Foss F, Isufi I, Kothari S, Ding W, Brander D, Sitlinger A, Rosenthal A, Leis J, Tun H, Kennard K, Nelson A, Falco V, Komari C, Koehler A, Stowe R, He W, Kearney A, Gui M, McKinlay T, Roeker L, Thompson M, Huntington S. A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-138896.Peer-Reviewed Original ResearchB-cell lymphomaChronic lymphocytic leukemiaLarge B-cell lymphomaR DLBCLStem cell transplantDuration of responseRichter transformationCombination therapyPrior therapyUnmet medical needTriple combinationPrimary endpointOverall survivalF. Hoffmann-La RocheMedian age 71 yearsMedical needTyrosine kinase inhibitor monotherapyDe novo diffuse large B-cell lymphomaNovo diffuse large B-cell lymphomaIndolent B-cell lymphomaAdvisory CommitteeMajor unmet medical needDiffuse large B-cell lymphomaHoffmann-La RochePhase ICost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020, 136: 1946-1955. PMID: 32518952, DOI: 10.1182/blood.2020004922.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioHealth care costsFirst-line ibrutinibLifetime direct health care costsCare costsCost-effectiveness ratioParametric survival modelingUnselected older adultsDirect health care costsUS payer perspectiveCurrent pricingLife yearsFixed-duration treatmentIncremental costIncremental effectivenessPayer perspectiveHigher health care costsIbrutinib armScenario analysisMonthly costCostPricingChronic lymphocytic leukemiaMarkov modelCost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaPola-BRR DLBCLRefractory diffuse large B-cell lymphomaLonger progression-free survivalRecent phase II trialDiffuse large B-cell lymphomaProgression-free survivalTransplant-ineligible patientsPhase II trialUS payer perspectiveCost-effectiveness ratioII trialOverall survivalTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessIncremental costPolatuzumabRituximabLymphomaDLBCL